Personalized Treatment Plan for Relapsed or Resistant AML
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AML (acute myeloid leukemia) that has returned or stopped responding to prior treatments
- You are at least 18 years old and in reasonably good overall health (able to carry out light activities)
- Your doctors believe you will likely survive at least 100 days
- You can provide a bone marrow sample or blood sample with enough leukemia cells for testing
- You have recovered from serious side effects of previous cancer treatments
- You are willing to consent to the study and allow use of your tumor tissue samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that uses your own immune cells (T cells) that have been changed in the lab to find and attack leukemia cells that have a marker called CD84. It is for people whose acute myeloid leukemia (AML) has returned or not responded to standard treatments.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This study tests a new experimental drug (NMS-03597812) for adults with AML that has not responded to or has returned after other treatments. The goal is to see if it is safe and if it can help control the leukemia.
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
This study compares two different treatments for people whose AML did not go away with initial therapy or came back early. It aims to find which approach works better.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.